HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Supplement Own-Labeler’s GMP Stumble Reveals AER Slip

This article was originally published in The Rose Sheet

Executive Summary

FDA warns own-labelers ProSupps USA and Cape Fear Naturals about GMP violations, also pointing out ProSupps dropped the ball on submitting serious AERs to FDA and Cape Fear Naturals made drug claims including “improve blood pressure and cholesterol.”

You may also be interested in...

Market America Asked To Comb Records For Serious AERs About Its Supplements

An FDA inspection found two serious adverse event reports Market America received were not forwarded to the agency as required. Its response didn't answer whether it would review its records "to determine if a serious adverse event report should be submitted to FDA.”

Study Suggests ‘Serious’ Events Are Rare Among All Supplement Adverse Events

Serious adverse events accounted for less than 1% of 41,121 adverse events reported to two supplement firms over 2.5 years, with weight loss agents and products for glycemic management accounting for majority, says a study by regulatory compliance consultants and CRN executives.

GMP Documentation, Identity Testing Continue To Trip Supplement Firms

Warnings from FDA's Office of Regulatory Affairs make clear that failing to document compliance with each GMP requirement renders those parts of the process noncompliant. Warning letters posted March 22 also include FDA's latest enforcement against firms marketing bulk caffeine.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts